Researchers from multiple clinical programs will present new scientific evidence in 20 presentations at ASTRO 2023, including two oral presentations, supporting the potential of SCINTIX therapy, which is delivered only through RefleXion's X1 platform. (Photo: Business Wire)
September 28, 2023 — RefleXion Medical, a therapeutic oncology company, announced the company will showcase the RefleXion X1 with SCINTIX biology-guided radiotherapy at the American Society for Radiation Oncology (ASTRO) Annual Meeting, Oct. 1-4, 2023 in San Diego (booth #2831). Researchers from multiple clinical programs will present new scientific evidence in 20 presentations, including two oral presentations, supporting the potential of SCINTIX therapy, which is delivered only through the X1 platform.
“We’re thrilled to see a robust and growing body of evidence about SCINTIX therapy as we commence patient treatments at multiple sites in the U.S. following FDA clearance of our technology earlier this year,” said Shervin “Sean” Shirvani, M.D., M.P.H., chief medical officer at RefleXion. “Highlights from these presentations explore critical aspects of X1 performance in dosimetric accuracy, workflow, FDG uptake, and exquisite kVCT image quality.
“Furthermore, we are now developing PSMA-targeted and FAP-targeted PET radiotracers as SCINTIX bioguides and are excited about the emerging results that will be presented at this meeting,” continued Shirvani.
The following oral and panel presentations highlight some of the new research being presented at ASTRO 2023. Detailed information on all 20 presentations may be found here.
Oral Presentations:
- Monday, Oct 2, 5:30-5:37 pm, Room 31 – Prognostic Significance of Positron Emission Tomography Delta Radiomics Following Bridging Therapy in Patients with Large B-Cell Lymphoma Undergoing CAR T-Cell Therapy
- Tuesday, Oct. 3, 4:20-4:25 pm, Room 4 – Mitigation of IMRT/SBRT Treatment Planning Errors on the First Biology-guided Radiotherapy System Using FMEA within Six Sigma Framework
Featured Posters:
- Monday, Oct. 2, 5:00-6:00 pm, Hall B2 – Evaluation of 68Ga-Fibroblast Activation Protein Inhibitor (FAP) vs. 18F-FDG as a Novel Radiotracer for Biologically-guided Radiation Therapy
- Tuesday, Oct. 3, 12:30-1:45 pm, Hall B2 – Dosimetric Accuracy of Multi-Target Biology-guided Radiotherapy Treatments in a Single Session
- Tuesday, Oct. 3, 2:30-3:45 pm, Hall B2 – Pilot Study of a Novel Ring Gantry-Based PET/CT Linear Accelerator in Patients with Prostate Cancer Receiving [18F]-DCFPyl for PSMA PET Imaging
- Wednesday, Oct. 4, 12:30-1:45 pm, Hall B2 – Imaging Performance of the PET scan on a Novel Ring Gantry-based PET/CT Linear Accelerator System in the First-in-Human Study of Biology-guided Radiotherapy
- Wednesday, Oct. 4, 12:30-1:45 pm, Hall B2 – Reproducibility and Repeatability of Pelvic Radiomics Features with Daily Imaging on a Novel Biology-guided Radiotherapy Machine Compared to Daily Imaging on Other Radiotherapy Delivery Systems
RefleXion will host in-booth presentations discussing their first patient treatments delivered in patients with lung tumors. Registration for these small-group presentations is recommended, and the schedule can be found here. The RefleXion booth will also feature a multi-target SCINTIX technology interactive demonstration and SCINTIX treatment planning demonstrations.
For more information: www.reflexion.com
September 29, 2026 
